Authors:György T. Szeifert, Hong Xun Han, Lixin Lin, Mi Zhi Quiang, Guang Hua Lou, and István Nyáry
A new digital Cobalt-60 combined stereotactic radiotherapy and radiosurgery system, termed as the GyroKnife, was developed in Shanghai, China in 2004. The equipment integrates advantages of previous generations of gamma radiosurgery techniques and linear accelerators. The technology has the capacity for non-invasive whole-body stereotactic fractionated radiotherapy and single high-dose radiosurgery as well. Using a triple focussing method, high isocenter accuracy (0.5~1.0 mm) and minimal skin (550:1) or normal tissue irradiation dose were achieved with 4 various sizes of collimator sets (5, 15, 25, 50 mm). The first GyroKnife Center in Kang Da Hospital, Xiang Fan, China, has already treated 100 cases with different tumours in the brain and body since November 2006. The technical details of the system will be presented, and the preliminary clinical results will also be discussed.
Authors:Mihály Patyánik, Norbert Solymosi, Nóra Bégányi, Dániel Sinkó, and Árpád Mayer
preoperative radiotherapy in rectal cancer patients: assessment of acute toxicity and treatment compliance. Report of the 22921 randomised trial conducted by the EORTC Radiotherapy Group. Eur. J. Cancer, 2004,
Ngan, S. Y., Burmeister, B., Fisher, R. J., et al.: Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans
Authors:Zsuzsanna Kahán, Zoltán Varga, Melinda Csenki, Júlia Szabó, Elemér Szil, Gábor Fekete, Katalin Hideghéty, Krisztina Boda, and László Thurzó
Early Breast Cancer Trialists’ Collaborative Group:
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomized trials. Lancet, 2005,
Authors:P. Jehenson, V. Lewington, C. Fallais, E. Lartigau, and J. Guidez
Nuclear medicine and radiotherapy make a vital contribution to the diagnosis and treatment of major disease. This role is likely to expand with new developments including availability of new medical isotopes. A European network (EMIR) was initiated in 2001 by the Joint Research Centre (JRC) of the European Commission, to identify and solve difficulties that constrain nuclear medicine and radiotherapy development in Europe and facilitate closer interdisciplinary collaboration. Participating organisations include the main European associations of medical radiation specialists, radiopharmaceutical/radioisotope producers, nuclear research reactor institutions, research organizations and the JRC. The steering committee established task groups focusing on eight key areas for development. Liaison with non-European organizations will be encouraged.
Authors:D. Ma, A. Ketring, G. Ehrhardt, and W. Jia
Many lanthanide radionuclides, having various nuclear properties but similar chemical properties, are considered suitable for different radiotherapeutic applications. This paper describes the production of a number of radiolanthanides (e.g.153Sm,166Dy,166Ho,161Tb and177Lu) and the radiotherapy research involving these radionuclides at the University of Missouri Research Reactor Center (MURR).